Abstract P5-18-26: Confirmatory overall survival (OS) analysis of CLEOPATRA: a randomized, double-blind, placebo-controlled Phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (1L) metastatic breast cancer (MBC)

Mapping Intimacies ◽

10.1158/0008-5472.sabcs12-p5-18-26 ◽

2012 ◽

Cited By ~ 5

Author(s):

SM Swain ◽

S-B Kim ◽

J Cortes ◽

J Ro ◽

V Semiglazov ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Her2 Positive ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study

Download Full-text

Cardiac Tolerability of Pertuzumab Plus Trastuzumab Plus Docetaxel in Patients With HER2‐Positive Metastatic Breast Cancer in CLEOPATRA: A Randomized, Double‐Blind, Placebo‐Controlled Phase III Study

The Oncologist ◽

10.1634/theoncologist.2012-0448 ◽

2013 ◽

Vol 18 (3) ◽

pp. 257-264 ◽

Cited By ~ 86

Author(s):

Sandra M. Swain ◽

Michael S. Ewer ◽

Javier Cortés ◽

Dino Amadori ◽

David Miles ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Her2 Positive ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study

Download Full-text

Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer

European Journal of Cancer ◽

10.1016/j.ejca.2017.10.018 ◽

2018 ◽

Vol 90 ◽

pp. 153-155 ◽

Cited By ~ 6

Author(s):

David Miles ◽

David Cameron ◽

Magalie Hilton ◽

Josep Garcia ◽

Joyce O'Shaughnessy

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo

Download Full-text

Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study

Breast Cancer Research and Treatment ◽

10.1007/s10549-020-05728-w ◽

2020 ◽

Vol 182 (3) ◽

pp. 689-697

Author(s):

Binghe Xu ◽

Wei Li ◽

Qingyuan Zhang ◽

Zhimin Shao ◽

Qiao Li ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Chinese Patients ◽

Controlled Study ◽

Her2 Positive ◽

Double Blind ◽

Double Blind Placebo ◽

Locally Recurrent

Download Full-text

Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO.

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.lba1011 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. LBA1011-LBA1011 ◽

Cited By ~ 87

Author(s):

D. Miles ◽

A. Chan ◽

G. Romieu ◽

L. Y. Dirix ◽

J. Cortes ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

First Line Therapy ◽

Line Therapy ◽

Phase Iii Study ◽

Locally Recurrent

Download Full-text

Randomized phase III study of trastuzumab monotherapy followed by docetaxel and trastuzumab versus the combination of trastuzumab and docetaxel as first-line treatment in patients with HER2 positive metastatic breast cancer.

10.1158/0008-5472.sabcs-3132 ◽

2009 ◽

Cited By ~ 3

Author(s):

K Najagami ◽

K Inoue ◽

M Mizutani ◽

Y Hozumi ◽

Y Fujiwara ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Phase Iii Study ◽

Trastuzumab Monotherapy ◽

First Line Treatment

Download Full-text

Final Overall Survival (OS) Results from the Randomised, Double-Blind, Placebo-Controlled, Phase III AVADO Study of Bevacizumab (BV) Plus Docetaxel (D) Compared with Placebo (PL) Plus D for the First-Line Treatment of Locally Recurrent (LR) or Metastatic Breast Cancer (mBC).

10.1158/0008-5472.sabcs-09-41 ◽

2009 ◽

Cited By ~ 15

Author(s):

D. Miles ◽

A. Chan ◽

G. Romieu ◽

L. Dirix ◽

J. Cortés ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

Locally Recurrent ◽

First Line Treatment

Download Full-text

Abstract P6-14-05: Final Overall Survival Analysis of the TBP Phase III Study (GBG 26/BIG 3-05): Capecitabine vs. Capecitabine + Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing during Trastuzumab Treatment

10.1158/0008-5472.sabcs10-p6-14-05 ◽

2010 ◽

Author(s):

G von Minckwitz ◽

K Schwedler ◽

M Schmidt ◽

J Barinoff ◽

C Mundhenke ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Survival Analysis ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Her2 Positive ◽

Trastuzumab Treatment ◽

Phase Iii Study ◽

Overall Survival Analysis

Download Full-text

1866 First results from the double-blind placebo (PL)-controlled randomised phase III MERiDiAN trial prospectively evaluating plasma (p)VEGF-A in patients (pts) receiving first-line paclitaxel (PAC) +/- bevacizumab (BV) for HER2-negative metastatic breast cancer (mBC)

European Journal of Cancer ◽

10.1016/s0959-8049(16)30816-4 ◽

2015 ◽

Vol 51 ◽

pp. S287-S288 ◽

Cited By ~ 6

Author(s):

D. Miles ◽

D. Cameron ◽

I. Bondarenko ◽

M. Lyudmila ◽

J.C. Alcedo ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

First Results

Download Full-text

S5-5: A Phase III, Randomized, Double-Blind, Placebo-Controlled Registration Trial To Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Patients with Previously Untreated HER2−Positive Metastatic Breast Cancer (CLEOPATRA).

10.1158/0008-5472.sabcs11-s5-5 ◽

2011 ◽

Cited By ~ 3

Author(s):

J Baselga ◽

S-B Kim ◽

S-A Im ◽

R Hegg ◽

Y-H Im ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Efficacy And Safety ◽

Her2 Positive ◽

Double Blind ◽

Double Blind Placebo ◽

Registration Trial

Download Full-text

Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)

Breast Cancer Research and Treatment ◽

10.1007/s10549-013-2710-z ◽

2013 ◽

Vol 142 (1) ◽

pp. 89-99 ◽

Cited By ~ 39

Author(s):

David Miles ◽

José Baselga ◽

Dino Amadori ◽

Patrapim Sunpaweravong ◽

Vladimir Semiglazov ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Older Patients ◽

Metastatic Breast ◽

Phase Iii ◽

Her2 Positive ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Subgroup Analyses

Download Full-text